FIBRINOLYSIS DOWN UNDER
Fundamental Aspects and translational opportunities
11-14 November 2024
Byron Bay, NSW, Australia
Byron Bay, NSW, Australia
ISTH funded Fundamental Research Workshop
Photo by Gustavo Barbosa on Unsplash
Fibrinolysis down under
Fundamental aspects and translational opportunities
We look forward to welcoming you to Byron Bay, NSW, in November 2024!
We are immensely proud to invite you to the inaugural ISTH-funded Fundamental Research Workshop titled "Fibrinolysis down under: Fundamental aspects and translational opportunities" that will be held from November 11-14, 2024, in the beautiful and picturesque seaside town of Byron Bay, in northern NSW, Australia. Byron Bay is the eastern most point of Australia. Please follow this link for general information about Byron Bay https://www.visitbyronbay.com/
The meeting venue will be the Byron Bay Theatre and Community Centre which is in the centre for Byron Bay,
The story behind this workshop
The field of fibrinolysis has gained significant momentum in recent years. It plays a crucial role in removing blood clots in thromboembolic conditions and influencing bleeding in hyperfibrinolytic conditions. Moreover, its role in various other biological areas, including immunity, inflammation, brain function, malignancy, and metabolism, is becoming increasingly recognized.
The following topics will be covered during the meeting
1. Cell and platelet surface plasminogen activation
2. New assays for fibrinolysis
3. Immunity, inflammation and wound healing
4. New indications for anti-fibrinolytic agents: basic and clinical aspects
5. Trauma, critical care, transplant
6. Ischaemic stroke: Animal models, new thrombolytic agents, adjunctive treatments
7. Malignancy
This workshop is open to everyone, with a specific focus on early and mid-career researchers in the region.
Note: A limited number of travel bursaries will be made available to students and early career scientists (<7 years postdoc) who have abstracts accepted.
Australian ECRs: $AUD500
New Zealand ECRs: $AUD750
Overseas ECRs: $AUD2000.
Further details can be found on the registration page.
ALSO please note that THANZ members may also apply for a Aus $1,000 travel grant to attend the Workshop. Applications must be made via the THANZ web site here: (https://www.thanz.org.au/awards-grants/awards/thanz-fibrinolysis-workshop-travel-grant/ ) and must be submitted by 4th October. Results will be announced by mid-October
The program will feature a diverse range of keynote speakers and moderators who will discuss the latest advancements in the field.
We will also have oral and poster sessions for presenting your research findings.
What to expect:
Please note:
We look forward to seeing you in Byron Bay!
We are immensely proud to invite you to the inaugural ISTH-funded Fundamental Research Workshop titled "Fibrinolysis down under: Fundamental aspects and translational opportunities" that will be held from November 11-14, 2024, in the beautiful and picturesque seaside town of Byron Bay, in northern NSW, Australia. Byron Bay is the eastern most point of Australia. Please follow this link for general information about Byron Bay https://www.visitbyronbay.com/
The meeting venue will be the Byron Bay Theatre and Community Centre which is in the centre for Byron Bay,
The story behind this workshop
The field of fibrinolysis has gained significant momentum in recent years. It plays a crucial role in removing blood clots in thromboembolic conditions and influencing bleeding in hyperfibrinolytic conditions. Moreover, its role in various other biological areas, including immunity, inflammation, brain function, malignancy, and metabolism, is becoming increasingly recognized.
The following topics will be covered during the meeting
1. Cell and platelet surface plasminogen activation
2. New assays for fibrinolysis
3. Immunity, inflammation and wound healing
4. New indications for anti-fibrinolytic agents: basic and clinical aspects
5. Trauma, critical care, transplant
6. Ischaemic stroke: Animal models, new thrombolytic agents, adjunctive treatments
7. Malignancy
This workshop is open to everyone, with a specific focus on early and mid-career researchers in the region.
Note: A limited number of travel bursaries will be made available to students and early career scientists (<7 years postdoc) who have abstracts accepted.
Australian ECRs: $AUD500
New Zealand ECRs: $AUD750
Overseas ECRs: $AUD2000.
Further details can be found on the registration page.
ALSO please note that THANZ members may also apply for a Aus $1,000 travel grant to attend the Workshop. Applications must be made via the THANZ web site here: (https://www.thanz.org.au/awards-grants/awards/thanz-fibrinolysis-workshop-travel-grant/ ) and must be submitted by 4th October. Results will be announced by mid-October
The program will feature a diverse range of keynote speakers and moderators who will discuss the latest advancements in the field.
We will also have oral and poster sessions for presenting your research findings.
What to expect:
- Keynote presentations by leading experts in fibrinolysis research
- Interactive sessions for discussing the latest findings and challenges
- Opportunities to network with colleagues from around the world
Please note:
- The workshop program, and some additional accommodation options will be available soon.
- The number of participants is limited, so be sure to submit your abstract and register early!
We look forward to seeing you in Byron Bay!
Registration includes morning tea, lunch and afternoon tea.
EARLY BIRD REGISTRATION DEADLINE Sept 27, 2024
EARLY BIRD REGISTRATION DEADLINE Sept 27, 2024
Location
Byron Bay Theatre and Community Centre
69 Jonson St, Byron Bay NSW 2481, Australia
69 Jonson St, Byron Bay NSW 2481, Australia
Date & Time
November 11, 2024, 4:00 PM - November 14, 2024 - 12:30 PM
Abstract submission
Abstract submission deadline has been extended to August 30, 2024.
Guidelines for submission:
250 word limit:
Include author list and affiliations.
Headings Background, Aims, Methods Results, Conclusions.
One figure or table is permitted
Please send abstract to the following email address:
[email protected]
or to [email protected]
Indicate in the Subject line: Abstract_ Surname of presenting author.
Please also indicate if you prefer a poster or oral presentation.
Guidelines for submission:
250 word limit:
Include author list and affiliations.
Headings Background, Aims, Methods Results, Conclusions.
One figure or table is permitted
Please send abstract to the following email address:
[email protected]
or to [email protected]
Indicate in the Subject line: Abstract_ Surname of presenting author.
Please also indicate if you prefer a poster or oral presentation.
KEY DATES
Registration is now open
Registration closes:
25th Oct 2024
Registration closes:
25th Oct 2024
Byron Bay
Byron Bay is a coastal town located on the eastern most tip of the Australian state of New South Wales. It’s a popular holiday destination, known for its beaches, surfing and scuba diving sites. Cape Byron State Conservation Park is on a headland with a lighthouse. Between June and November, humpback whales can be spotted from headland viewpoints such as the Captain Cook Lookout.
Invited speakers
Keynote speaker
Professor David Vaux, Walter and Eliza Hall Institute of Medical Research (WEHI), Australia
International speakers
Dr. Dominik Draxler, Inselspital, Bern, Switzerland
Professor Beverley Hunt, King's College, London, UK
Dr. Takayuki Iwaki, Hamamatsu University School of Medicine, Hamamatsu, Japan
Professor Alisa Wolberg, University of North Carolina, Chapel Hill USA
Professor Nicola Mutch, University of Aberdeen, UK
Professor Tetsu Urano, Hamamatsu University School of Medicine, Hamamatsu, Japan
Professor Yuko Suzuki, Hamamatsu University School of Medicine, Hamamatsu, Japan
A/Professor Chris Barrett, University of Nebraska Medical Centre, USA
Professor Daniel Lawrence, University of Michigan, USA
A/Professor Ze Zheng, Medical College of Wisconsin, USA
A/Professor Paul Kim, McMaster University, Hamilton, CAN
Dr. Evert Loef University of Auckland, New Zealand
Dr. James Hucklesby, University of Auckland, New Zealand
Local speakers
Prof Bruce Campbell, Department of Neurology & Melbourne Brain Centre, Royal Melbourne Hospital
Prof Christoph Hagemeyer, Australian Centre for Blood Diseases, Monash University
A/Prof Connie Wong, Centre for Inflammatory Diseases, Department of Medicine, Monash University
Prof Biswadev Mitra, Head, Emergency Research Unit, Alfred Health Emergency Service, Alfred Hospital
Prof Paul Myles, Perioperative Medicine and Anaesthesiology, Alfred Hospital and Monash University
Prof Zoe McQuilten, School of Public Health and Preventative Medicine, Monash University
Prof Marie Ranson, University of Wollongong, NSW, Australia
A/Prof Ruby Law, Department of Biochemistry and Molecular Biology, Monash University
Prof Rob Medcalf, Australian Centre for Blood Diseases, Monash University
Dr. Cherry Keragala, Australian Centre for Blood Diseases, Monash University
Prof Geoffrey Cloud, Department of Neurosciences, Monash University, Head of Stroke Unit, Alfred Hospital
Dr. Lucy Coupland, Ingham Institute for Applied Medical Research and Liverpool Hospital, NSW, Australia
Professor David Vaux, Walter and Eliza Hall Institute of Medical Research (WEHI), Australia
International speakers
Dr. Dominik Draxler, Inselspital, Bern, Switzerland
Professor Beverley Hunt, King's College, London, UK
Dr. Takayuki Iwaki, Hamamatsu University School of Medicine, Hamamatsu, Japan
Professor Alisa Wolberg, University of North Carolina, Chapel Hill USA
Professor Nicola Mutch, University of Aberdeen, UK
Professor Tetsu Urano, Hamamatsu University School of Medicine, Hamamatsu, Japan
Professor Yuko Suzuki, Hamamatsu University School of Medicine, Hamamatsu, Japan
A/Professor Chris Barrett, University of Nebraska Medical Centre, USA
Professor Daniel Lawrence, University of Michigan, USA
A/Professor Ze Zheng, Medical College of Wisconsin, USA
A/Professor Paul Kim, McMaster University, Hamilton, CAN
Dr. Evert Loef University of Auckland, New Zealand
Dr. James Hucklesby, University of Auckland, New Zealand
Local speakers
Prof Bruce Campbell, Department of Neurology & Melbourne Brain Centre, Royal Melbourne Hospital
Prof Christoph Hagemeyer, Australian Centre for Blood Diseases, Monash University
A/Prof Connie Wong, Centre for Inflammatory Diseases, Department of Medicine, Monash University
Prof Biswadev Mitra, Head, Emergency Research Unit, Alfred Health Emergency Service, Alfred Hospital
Prof Paul Myles, Perioperative Medicine and Anaesthesiology, Alfred Hospital and Monash University
Prof Zoe McQuilten, School of Public Health and Preventative Medicine, Monash University
Prof Marie Ranson, University of Wollongong, NSW, Australia
A/Prof Ruby Law, Department of Biochemistry and Molecular Biology, Monash University
Prof Rob Medcalf, Australian Centre for Blood Diseases, Monash University
Dr. Cherry Keragala, Australian Centre for Blood Diseases, Monash University
Prof Geoffrey Cloud, Department of Neurosciences, Monash University, Head of Stroke Unit, Alfred Hospital
Dr. Lucy Coupland, Ingham Institute for Applied Medical Research and Liverpool Hospital, NSW, Australia
Program
MONDAY 11 NOVEMBER 2024
1400 - 1700
Registration
1700 - 1830
Opening ceremony
Welcome address
Rob Medcalf, Tetsu Urano, Cherry Keragala, & Yuko Suzuki
Keynote Lecture: Scientists behaving badly
Professor David Vaux (AUS)
Introduced by Rob Medcalf
Introduced by Rob Medcalf
Science is knowledge gained through repeated observation or experiment. It is communicated through publication of papers in journals. Science can only flourish if its results are reproducible, journals maintain minimal standards, and papers are read critically. This talk will provide some examples of where this can go wrong, and will be illustrated by examples of papers by high profile researchers in prestigious journals that would only have had some value had they been printed on absorbent paper with perforated pages.
1830 - 2100
Welcome reception
TUESDAY 12 NOVEMBER 2024
0800 - 0830
Registration
0830 - 1000
Session 1: The changing landscape of fibrinolysis
Chairs: Tetsu Urano, Cherry Keragala
Plasminogen: Basics and beyond
Ruby Law (AUS) – 30 mins
Reciprocal regulation of lipoproteins and fibrinolysis
Ze Zheng (USA) – 30 mins
Thrombolysis exacerbates cerebrovascular injury after ischemic stroke via a VEGF-b dependent effect on adipose lipolysis
Dan Lawrence (USA) – 30 mins
Ruby Law (AUS) – 30 mins
Reciprocal regulation of lipoproteins and fibrinolysis
Ze Zheng (USA) – 30 mins
Thrombolysis exacerbates cerebrovascular injury after ischemic stroke via a VEGF-b dependent effect on adipose lipolysis
Dan Lawrence (USA) – 30 mins
1000 - 1030
Morning Tea
1030 - 1200
Session 2: Thrombolysis and adjunctive treatments: Ischaemic stroke and Pulmonary embolism
Chairs: Geoff Cloud and Anna Balabanski
Non-fibrinolytic adjuvants for stroke thrombolysis
Bruce Campbell (AUS) – 25 mins
Alpha2-Antiplasmin inhibition and the promise for improving fibrinolysis treatment in acute ischemic stroke
Greg Makris (Bayer, UK) – 25 mins
The individual fibrinolytic capacity predicts efficacy of ultrasound-assisted catheter-directed thrombolysis in patients with acute pulmonary embolism
Dominik Draxler (CH) – 25 mins
Platelet-derived nanoparticles for targeted destruction of NETs in thrombi
Samantha Loong (selected abstract) – 15 mins
Bruce Campbell (AUS) – 25 mins
Alpha2-Antiplasmin inhibition and the promise for improving fibrinolysis treatment in acute ischemic stroke
Greg Makris (Bayer, UK) – 25 mins
The individual fibrinolytic capacity predicts efficacy of ultrasound-assisted catheter-directed thrombolysis in patients with acute pulmonary embolism
Dominik Draxler (CH) – 25 mins
Platelet-derived nanoparticles for targeted destruction of NETs in thrombi
Samantha Loong (selected abstract) – 15 mins
1200 - 1300
Lunch
1300 - 1430
Session 3: Ischaemic stroke (Basic Science I)
Chairs: Connie Wong, James Hucklesby
Using intravital microscopy to study host responses to stroke
Connie Wong (AUS) – 25 mins
Comparison of generic forms of Tenecteplase
Rob Medcalf (AUS) – 25 mins
Smart nano-materials and fusion-molecules for targeted fibrinolysis
Christoph Hagemeyer (AUS) – 25 mins
Engineering hyperechogenic colloids with thrombus-targeting capabilities from platelet membranes
Mitch Moon (selected abstract) – 15 mins
Connie Wong (AUS) – 25 mins
Comparison of generic forms of Tenecteplase
Rob Medcalf (AUS) – 25 mins
Smart nano-materials and fusion-molecules for targeted fibrinolysis
Christoph Hagemeyer (AUS) – 25 mins
Engineering hyperechogenic colloids with thrombus-targeting capabilities from platelet membranes
Mitch Moon (selected abstract) – 15 mins
1430 - 1500
Afternoon Tea
1500 - 1610
Session 4: Ischaemic stroke (Basic Science II)
Chairs: Helena Kim, Chris Levi
Investigating the effect of plasminogen system proteins on the barrier integrity of human brain microvascular endothelial monolayers in real time
James Hucklesby (NZ) – 25 mins
Brain-resident and not infiltrating cells drive acute neuroinflammation post-ischaemic stroke
Josh Bourne (selected abstract) – 15 mins
Dual-Drug Loaded Nanoparticles for Enhanced Thrombolysis
Xiangxun Chen (selected abstract) – 15 mins
Acute inflammation occurs in brain regions distal to the ischaemic core following photothrombotic stroke
Charlotte Barker (selected abstract) – 15 mins
James Hucklesby (NZ) – 25 mins
Brain-resident and not infiltrating cells drive acute neuroinflammation post-ischaemic stroke
Josh Bourne (selected abstract) – 15 mins
Dual-Drug Loaded Nanoparticles for Enhanced Thrombolysis
Xiangxun Chen (selected abstract) – 15 mins
Acute inflammation occurs in brain regions distal to the ischaemic core following photothrombotic stroke
Charlotte Barker (selected abstract) – 15 mins
1610 - 1715
Poster viewing session I
Moderators: Anton Ilich, Marie Ranson
Assessment of plasmin generation in patients with chronic kidney disease
Vincent Lu (AUS)
Assessment of plasmin generation in patients with diabetes mellitus
Vincent Lu (AUS)
Development of a platelet-derived clot-targeted drug carrier for effective and safe fibrinolysis
Julia Skoraczynsk (AUS)
Investigating the composition of endovascularly retrieved clots to determine stroke aetiology (THROMBUS Study)
Rebecca J Hood (AUS)
Inflammatory Degradation of Plasminogen Impairs Fibrinolysis in Pleural Space Infections
Peter K Moore MD (USA)
Early systemic administration of a natural carboxypeptidase inhibitor potentiates tPA-mediated thrombolysis: Evidence from real-time intravital imaging analysis of microthrombi in mice
Nitty Skariah Mathews (JPN/India)
Platelet additive solutions alter whole blood and plasma clot stability
Gael B Morrow (UK)
Vincent Lu (AUS)
Assessment of plasmin generation in patients with diabetes mellitus
Vincent Lu (AUS)
Development of a platelet-derived clot-targeted drug carrier for effective and safe fibrinolysis
Julia Skoraczynsk (AUS)
Investigating the composition of endovascularly retrieved clots to determine stroke aetiology (THROMBUS Study)
Rebecca J Hood (AUS)
Inflammatory Degradation of Plasminogen Impairs Fibrinolysis in Pleural Space Infections
Peter K Moore MD (USA)
Early systemic administration of a natural carboxypeptidase inhibitor potentiates tPA-mediated thrombolysis: Evidence from real-time intravital imaging analysis of microthrombi in mice
Nitty Skariah Mathews (JPN/India)
Platelet additive solutions alter whole blood and plasma clot stability
Gael B Morrow (UK)
1730
OTHERWORLD: Art and Light Experience
102 Jonson St. Byron Bay
WEDNESDAY 13 NOVEMBER 2024
0800 - 0830
Registration
0830 - 1000
Session 5: Tranexamic acid: New opportunities I
Chairs: Zoe McQuilten, Dominik Draxler
The future of TXA
Beverley Hunt (UK) – 25 mins
Current thinking on tranexamic acid
Prof. Paul Myles (AUS) – 25 mins
Dose and regimen of tranexamic acid after trauma: A secondary analysis of the PATCH-Trauma trial
Biswadev Mitra (AUS) – 25 mins
Tranexamic acid reduces mortality when given within 90 minutes of injury
Adnan Ali (selected abstract) – 15 mins
Beverley Hunt (UK) – 25 mins
Current thinking on tranexamic acid
Prof. Paul Myles (AUS) – 25 mins
Dose and regimen of tranexamic acid after trauma: A secondary analysis of the PATCH-Trauma trial
Biswadev Mitra (AUS) – 25 mins
Tranexamic acid reduces mortality when given within 90 minutes of injury
Adnan Ali (selected abstract) – 15 mins
100 - 1030
Morning Tea
1030 - 1200
Session 6: Tranexamic acid: New opportunities II
Chairs: Beverley Hunt, Gene Moore
TXA for Cerebral amyloid angiopathy: A novel secondary stroke prevention approach
Geoff Cloud (AUS) – 25mins
Tranexamic acid to prevent bleeding in haematology patients with thrombocytopenia: is there any role?
Zoe McQuilten (AUS) – 25 mins
Tranexamic acid to prevent bleeding in haematology patients with thrombocytopenia: is there any role?
Usha Gurunathan (selected abstract) – 15 mins
General discussion on TXA – 25 mins
Geoff Cloud (AUS) – 25mins
Tranexamic acid to prevent bleeding in haematology patients with thrombocytopenia: is there any role?
Zoe McQuilten (AUS) – 25 mins
Tranexamic acid to prevent bleeding in haematology patients with thrombocytopenia: is there any role?
Usha Gurunathan (selected abstract) – 15 mins
General discussion on TXA – 25 mins
1200 - 1300
Lunch
1300 - 1430
Session 7: Fibrinolysis and thrombosis in other indications
Chairs: Dan Lawrence, Ze Zheng
Environment and shear as master controllers of fibrinolysis
Nikki Mutch (UK) – 25 mins
PAI-1 deficiency due to intracellular polymer formation and to splice variants
Takayuki Iwaki (JPN) – 25 mins
The role of the plasminogen receptor Plg‑RKT in atherosclerotic development
Hans Wojta (Austria, selected abstract) – 25 mins
Intestinal mucosal microthrombus and inflammatory bowel disease
Yuko Suzuki (Japan) – 15 mins
Nikki Mutch (UK) – 25 mins
PAI-1 deficiency due to intracellular polymer formation and to splice variants
Takayuki Iwaki (JPN) – 25 mins
The role of the plasminogen receptor Plg‑RKT in atherosclerotic development
Hans Wojta (Austria, selected abstract) – 25 mins
Intestinal mucosal microthrombus and inflammatory bowel disease
Yuko Suzuki (Japan) – 15 mins
1430 - 1500
Afternoon Tea
1500 - 1630
Session 8: New assays to measure plasminogen activation and fibrinolysis in clinical samples
Chairs: Chris Barrett, Zikou Liu
A novel fibrinolysis resistance capacity assay successfully detected fibrinolytic phenotypes in trauma patients
Tetsu Urano (JPN) – 25 mins
Plasminogen activation assays and application to translational studies
Alisa Wolberg (USA) – 25 mins
Novel assay to quantify tranexamic acid levels in plasma and its potential applications
Paul Kim (CAN) – 25 mins
A novel rapid assay for the detection of acquired hyperfibrinolysis
Anton Ilich (selected abstract) – 15 mins
Tetsu Urano (JPN) – 25 mins
Plasminogen activation assays and application to translational studies
Alisa Wolberg (USA) – 25 mins
Novel assay to quantify tranexamic acid levels in plasma and its potential applications
Paul Kim (CAN) – 25 mins
A novel rapid assay for the detection of acquired hyperfibrinolysis
Anton Ilich (selected abstract) – 15 mins
1300 - 1430
Poster viewing session II
Moderators: Gael Morrow, Taka Iwaki
Hyperfibrinolysis Promotes Complement Activation After Traumatic Injury
Elizabeth R. Maginot (USA)
The spatiotemporal binding of conformation-specific ScFv-GPIIb/IIIa to platelet subpopulations and clot architecture
Thomas Montibeller (AUS)
Deficiency of ADAMTS13 leads to the formation of not tight but loose thrombus
Ippei Makita (JPN)
Roles of neuroserpin and α2-antiplasmin in neuroprotection and neurorestoration in neonatal and adult mouse models of cerebral ischaemia
Eri Kawashita (JPN)
Does Tranexamic acid reduce post-operative infection rates? planned studies for the TRIGS trial
Tammy Lam (AUS)
Assessment of high throughput fibrinolysis assays in vitro
Jane Arthur (AUS)
Elizabeth R. Maginot (USA)
The spatiotemporal binding of conformation-specific ScFv-GPIIb/IIIa to platelet subpopulations and clot architecture
Thomas Montibeller (AUS)
Deficiency of ADAMTS13 leads to the formation of not tight but loose thrombus
Ippei Makita (JPN)
Roles of neuroserpin and α2-antiplasmin in neuroprotection and neurorestoration in neonatal and adult mouse models of cerebral ischaemia
Eri Kawashita (JPN)
Does Tranexamic acid reduce post-operative infection rates? planned studies for the TRIGS trial
Tammy Lam (AUS)
Assessment of high throughput fibrinolysis assays in vitro
Jane Arthur (AUS)
1900
Dinner
The Loft - 9/4 Jonson St. Byron Bay
THURSDAY 14 NOVEMBER 2024
0900 - 1030
Session 9: Fibrinolysis and Immunity
Chairs: Yuko Suzuki, Paul Kim
Human T cells and dendritic cells can utilise the fibrinolytic system to exert wide-ranging functional effects.
Evert Loef (NZ) – 30 mins
The role of fibrinolysis and antifibrinolytics in complement-mediated inflammatory responses after injury
Chris Barrett (USA) – 30 mins
Plasminogen Supplementation Improves Lysis of Inflammatory Retained Traumatic Hemothorax
Elizabeth R. Maginot (selected abstract) – 15 mins
Factor XIII-A augments inflammation and repair following acute lung injury
Peter Moore (selected abstract) – 15 mins
Evert Loef (NZ) – 30 mins
The role of fibrinolysis and antifibrinolytics in complement-mediated inflammatory responses after injury
Chris Barrett (USA) – 30 mins
Plasminogen Supplementation Improves Lysis of Inflammatory Retained Traumatic Hemothorax
Elizabeth R. Maginot (selected abstract) – 15 mins
Factor XIII-A augments inflammation and repair following acute lung injury
Peter Moore (selected abstract) – 15 mins
1030 - 1100
Morning Tea
1100 - 1205
Session 10: Modulation and detection of fibrinolysis for other indications: evidence from the laboratory
Chairs: Rob Medcalf, Alisa Wolberg
Selective Urokinase inhibition impedes pancreatic cancer growth and metastasis: effects on tumour- stellate cell crosstalk and immune cell infiltration
Marie Ranson (AUS) – 25 mins
Serial point-of-care measurement of fibrinolysis resistance in the critically ill: association with disease severity, impact upon patient outcomes, and exploration of mechanisms and treatment options.
Lucy Coupland (AUS) – 25 mins
Point of care assay for tPA-inducible fibrinolysis quantification
Ed Henderson (selected abstract) – 15 mins
Marie Ranson (AUS) – 25 mins
Serial point-of-care measurement of fibrinolysis resistance in the critically ill: association with disease severity, impact upon patient outcomes, and exploration of mechanisms and treatment options.
Lucy Coupland (AUS) – 25 mins
Point of care assay for tPA-inducible fibrinolysis quantification
Ed Henderson (selected abstract) – 15 mins
1205 - 1220
Closing Comments & Farewell
Rob Medcalf, Tetsu Urano, Cherry Keragala, & Yuko Suzuki
Accommodation
The congress organisers have arranged for a 5% discount at Outrigger Bay Apartments, but these are limited in number. Discounts are also available at "The Lord Byron" if bookings are made early.
It is recommended that attendees arrange their own accommodation early via usual booking channels.
It is recommended that attendees arrange their own accommodation early via usual booking channels.
Travel advice
The closest international airport to Byron Bay is Gold Coast Airport. It is also possible to get to Byron Bay via bus (~2h) from Brisbane Airport.
Byron Bay also has an airport that can be reached domestically from various cities including Sydney and Melbourne.
Shuttles are available from Byron Bay airport to Byron Bay town (~40 min)
Byron Bay also has an airport that can be reached domestically from various cities including Sydney and Melbourne.
Shuttles are available from Byron Bay airport to Byron Bay town (~40 min)
Contact Us
Prof. Robert Medcalf (Co-Chair)
Australia Centre of Blood Diseases, Monash University
Email: [email protected]
Dr. Charithani Keragala (Co-Chair)
Australia Centre of Blood Diseases, Monash University
Email: [email protected], [email protected]
Prof. Tetsumei Urano (Co-Vice Chair)
Hamamatsu University School of Medicine
Email: [email protected]
Prof. Yuko Suzuki (Co-Vice Chair)
Hamamatsu University School of Medicine
Email: [email protected]
Australia Centre of Blood Diseases, Monash University
Email: [email protected]
Dr. Charithani Keragala (Co-Chair)
Australia Centre of Blood Diseases, Monash University
Email: [email protected], [email protected]
Prof. Tetsumei Urano (Co-Vice Chair)
Hamamatsu University School of Medicine
Email: [email protected]
Prof. Yuko Suzuki (Co-Vice Chair)
Hamamatsu University School of Medicine
Email: [email protected]
Sponsors
